A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Clinical trial NCT07172802 · RECRUITING

Trial details

NCT number: NCT07172802
Sponsor: GI Innovation, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Metastatic Solid Tumor Non-small Cell Lung Cancer (NSCLC)Head and Neck (HNSCC)Pancreatic Cancer Renal Cell Carcinoma (RCC)

Start date: 2025-04-22
Primary completion: 2027-02-01
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.